{
  "abstract": "Objective: To evaluate the efficacy and safety of first-line third-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) combined with pemetrexed-platinum chemotherapy in patients with EGFR-mutant advanced lung adenocarcinoma and brain parenchymal metastases.\n\nMethods: A bicenter retrospective cohort study was conducted. A total of 150 eligible patients were enrolled and balanced by 1:1 propensity score matching. Tumor response, survival outcomes, and treatment-related adverse events were compared between groups.\n\nResults: After matching, 60 patients were assigned to each group. The intracranial objective response rate was 78.3% in the combination group versus 61.7% in the monotherapy group (P = 0.046). The median intracranial progression-free survival was 28.3 months in the combination group (hazard ratio = 0.536, 95% confidence interval: 0.350–0.820, P = 0.002). Systemic progression-free survival and overall survival were also significantly prolonged in the combination arm. Adverse events were predominantly chemotherapy-related toxicities and were generally manageable.\n\nConclusion: First-line third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy is associated with superior intracranial and systemic survival benefits in EGFR-mutant lung adenocarcinoma patients with brain parenchymal metastases, with a favorable safety profile. This study provides real-world evidence to support clinical treatment decision-making.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Head, Neck and Thoracic Oncology, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine-Hebei",
    "Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer",
    "Department of Thoracic Oncology, Tianjin Lung Cancer Center, Tianjin’s Clinical Research Center for Cancer, Tianjin Cancer Institute & Hospital, Tianjin Medical University",
    "Department of Urology, The Fifth People’s Hospital of Hengshui City"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0,
        1,
        2
      ],
      "name": "Jianxi Zhou"
    },
    {
      "affs": [
        3
      ],
      "name": "Yinghao Wang"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Kang Wen"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Chun Huang"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Tingting Qin"
    },
    {
      "affs": [
        2
      ],
      "name": "Yunchuan Sun"
    },
    {
      "affs": [
        1,
        2
      ],
      "name": "Peng Chen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/b5yt17nsztkr8.bib",
  "cited_by": 0,
  "doi": "10.3389/fphar.2026.1959801",
  "fulltext_url": "https://europepmc.org/articles/PMC13683676",
  "id": "b5yt17nsztkr8",
  "issns": [
    "1663-9812"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1959801/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7220844822",
  "pdf_url": "https://europepmc.org/articles/PMC13683676?pdf=render",
  "pmcid": "PMC13683676",
  "pmid": "42909031",
  "published": "2026-10-07",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/b5yt17nsztkr8.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:06Z",
      "native_id": "10.3389/fphar.2026.1959801",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fphar.2026.1959801/full"
    },
    {
      "first_seen": "2026-10-30T12:20:10Z",
      "native_id": "MED:42909031",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42909031"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:1663-9812",
      "subfield": "pharmacology-toxicology"
    }
  ],
  "title": "Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases",
  "title_text": "Third-generation EGFR-TKI plus pemetrexed-platinum chemotherapy versus TKI monotherapy as first-line treatment for EGFR-mutant lung adenocarcinoma with brain parenchymal metastases",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:20:10Z",
  "url": "https://research.draconitic.com/paper/b5yt17nsztkr8",
  "venue": "Frontiers in Pharmacology",
  "versions": []
}